{"id":"W2903493423","doi":"10.1016/s0140-6736(18)31999-8","title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","year":2018,"lang":"en","type":"article","venue":"The Lancet","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1697,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme; National Institute for Health and Care Research","keywords":"Cetuximab; Medicine; Docetaxel; Pembrolizumab; Oncology; Open label; Internal medicine; Head and neck; Methotrexate; Head and neck squamous-cell carcinoma; Head and neck cancer; Phases of clinical research; Chemotherapy; Randomized controlled trial; Surgery; Radiation therapy; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002593085,0.002252914,0.003252534,0.0005051712,0.0004794012,0.001344493,0.001358525,0.00206242,0.008900049],"category_scores_gemma":[0.002159353,0.001068005,0.003068115,0.0005118047,0.001384022,0.001884838,0.0005091557,0.004125957,0.001634837],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00126967,"about_ca_system_score_gemma":0.001230814,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002401483,"about_ca_topic_score_gemma":0.005056622,"domain_scores_codex":[0.9991639,0.0004654439,0.00004211467,0.0001384013,0.00005510549,0.0001349497],"domain_scores_gemma":[0.9991004,0.0003263183,0.0001918026,0.00007922717,0.00004822117,0.0002540347],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9822555,0.00362508,0.0001987864,0.0006171764,0.0009889737,0.00002468413,0.00004739645,0.0002759325,0.001487761,0.00008014671,0.0005481261,0.009850376],"study_design_scores_gemma":[0.9559578,0.04188263,0.0007959311,0.00003278189,0.0004987943,0.00002071265,0.00002097262,0.0001636859,0.0001715577,0.0001002501,0.0003430802,0.00001183273],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9817171,0.008142939,0.0007595223,0.0008006776,0.0008088212,0.003117093,0.001500868,0.0001603461,0.002992713],"genre_scores_gemma":[0.9812251,0.005219722,0.001613671,0.001405087,0.0004455772,0.002895682,0.001178501,0.00004304831,0.005973556],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008900049,"threshold_uncertainty_score":0.02977359,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1842592246262575,"score_gpt":0.4337317604657096,"score_spread":0.2494725358394521,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}